Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Alliance Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,174,812

82 payments

Through program year 2025, Alliance Clinical Research is reported as receiving $1,174,812 in research payments, across 82 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $26,850 4
2024 Research $4,275 1
2022 Research $13,545 2
2021 Research $61,154 16
2020 Research $328,752 32
2019 Research $740,236 27

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $583,290 24 payments
  2. Intercept Pharmaceuticals, Inc. $273,296 27 payments
  3. Akcea Therapeutics, Inc. $111,385 4 payments
  4. Eli Lilly and Company $92,800 7 payments
  5. Celgene Corporation $31,500 3 payments
  6. Amgen Inc. $26,850 4 payments
  7. AstraZeneca Pharmaceuticals LP $25,427 5 payments
  8. Gilead Sciences, Inc. $20,500 2 payments
  9. Pfizer Inc. $6,775 2 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $2,988 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $322,247 5 payments
  2. 1009742 $230,524 19 payments
  3. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $140,424 2 payments
  4. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $99,276 13 payments
  5. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (Nash) $74,874 3 payments
  6. Isis 703802-Cs2 $57,912 1 payment
  7. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD) $53,473 3 payments
  8. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) $29,228 6 payments
  9. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $20,555 4 payments
  10. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $19,922 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record